- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04966533
Characterize Metzker Pigmentary Disorders
July 7, 2021 updated by: University Hospital, Montpellier
Metzker pigmentary disorders are frequent cause of consultation in pediatric dermatology.
The investigators can describe 4 patterns.
They must be differentiated from mosaicisms because they aren't associated with neurologic disorders and don't require any follow up.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
74
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Montpellier, France, 34295
- UH Montpellier
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Children coming at the pediatric dermatology consultation with a Metkzer pigmentary disorder between 2005 and 2021
Description
Inclusion criteria:
- Metzker pigmentary disorder, age between birth and 18 years old
Exclusion criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metzker pigmentary disorder pattern
Time Frame: 1 day
|
Plume of smoke/ Cloud/Flag/ Linear
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Evolution
Time Frame: 1 day
|
Stability/ partial regression/aggravation
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Didier BESSIS, PhD, University Hospitals of Montpellier
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2005
Primary Completion (Actual)
January 30, 2021
Study Completion (Actual)
June 30, 2021
Study Registration Dates
First Submitted
July 5, 2021
First Submitted That Met QC Criteria
July 7, 2021
First Posted (Actual)
July 19, 2021
Study Record Updates
Last Update Posted (Actual)
July 19, 2021
Last Update Submitted That Met QC Criteria
July 7, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- RECHMPL21_0383
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
NC
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mosaicism
-
Stanford UniversityRecruitingPregnancy and Developmental Outcomes After Transfer of Reportedly Aneuploid or Mosaic Embryos (TAME)Aneuploidy | MosaicismUnited States
-
Ganin Fertility CenterUnknownInfertility | Mosaicism | Aneuploidy RateEgypt
-
Centre Hospitalier Universitaire DijonCompletedMalformations With Skin Manifestations Suggesting MosaicismFrance
-
University of California, San FranciscoCompletedInfertility | Embryonic Mosaicism | Embryo Culture Media | Embryo MorphokineticsUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); Baylor College of Medicine; City of Hope Medical...RecruitingTP53 Gene Mutation | Li-Fraumeni Syndrome | Hereditary Cancer Syndrome | Mosaicism | Clonal HematopoiesisUnited States
-
University of Colorado, DenverCompletedTurner Syndrome | Turner Syndrome Mosaicism, 45, X/46, XX or XY | Turner Syndrome Mosaicism 46,X,I(X)(Q10)/45,X | Turner Syndrome Karyotype 46,X With Abnormal Sex Chromosome , Except I(Xq)United States
-
University of Colorado, DenverRecruitingKlinefelter Syndrome | Trisomy X | XYY Syndrome | XXXY and XXXXY Syndrome | Xxyy Syndrome | Xyyy Syndrome | Xxxx Syndrome | Xxxxx Syndrome | Xxxyy Syndrome | Xxyyy Syndrome | Xyyyy Syndrome | Male With Sex Chromosome MosaicismUnited States